PubMed Health⌕ Search

Biomedical subjects

R W Jamieson

Publications and source records attributed to R W Jamieson.

7 recordsLinked to original sources

PBS140: new competition in the organ preservation market?

PBS140 offers good cold preservation in renal transplantation and now, crucially, has been shown to promote immediate function following warm ischemia. For a new cold preservation solution to compete with UW solution, improved efficacy and lower price may not be enough. Reducing rates of delayed graft function in organs from non-heart-beating and marginal donors might be the key.

Adenosine↗

International distance-learning outreach: the APEC EINet experience.

BACKGROUND: The Emerging Infections Network is a mature electronic network that links Public Health professionals in the Asia Pacific through regular e-mail bulletins and an extensive Web site (http://www.apec.org/infectious). Emerging infections is a new area of study; learning materials help foster education. Our objective is to quantify the response of the network to the introduction of distance-learning materials on the Web site. METHODS: Distance-learning materials, developed by the University of Washington School of Public Health, were field tested and launched on the site. Publicity was carried out prior to the launch of the materials. Access was tracked prospectively using server counts of page downloads. RESULTS: Web access increased substantially during the month after the materials were launched, especially among Asia based computers. The effect was isolated to the distance-learning pages, and not general to the site. CONCLUSIONS: This Web site appears to be responsive to the advertisement and to the materials. Prospective Web-site monitoring proved useful.

Asia↗

Pentazocine-naloxone experimenters among abusers of pentazocine and tripelennamine from a VA treatment population.

Psychiatric diagnostic profiles, drug and personal histories, and social support measures were obtained for a clinic sample of abusers of pentazocine when the drug was withdrawn and re-released by the manufacturer compounded with the opiate antagonist naloxone. Nearly 50% of the sample (N = 99) reported using the new drug during the following 6 to 9 months, despite its reduced abuse potential. Reinterviews revealed that claimed use of pentazocine dropped to half.

Adult↗